Clinical hematology international最新文献

Delivering bad news in clinical hematology: a personal perspective. 在临床血液学中传递坏消息：个人观点。

Clinical hematology international Pub Date : 2024-12-21 eCollection Date: 2024-01-01 DOI: 10.46989/001c.126214

Mohamad Mohty, Finn Bo Petersen, Didier Blaise

引用次数: 0

Role of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. 巨细胞病毒再激活在异基因造血干细胞移植后急性淋巴细胞白血病复发中的作用。

Clinical hematology international Pub Date : 2024-12-05 eCollection Date: 2024-01-01 DOI: 10.46989/001c.125912

Sabrine Mekni, Nour Ben Abdeljelil, Rihab Ouerghi, Rimmel Yosra Kanoun, Siwar Frigui, Dorra Belloumi, Insaf Ben Yaiche, Ines Turki, Anna Chabaane, Lamia Torjemane, Tarek Ben Othman

{"title":"Role of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia.","authors":"Sabrine Mekni, Nour Ben Abdeljelil, Rihab Ouerghi, Rimmel Yosra Kanoun, Siwar Frigui, Dorra Belloumi, Insaf Ben Yaiche, Ines Turki, Anna Chabaane, Lamia Torjemane, Tarek Ben Othman","doi":"10.46989/001c.125912","DOIUrl":"10.46989/001c.125912","url":null,"abstract":"Cytomegalovirus reactivation (CMV-R) is a frequent complication post-allogeneic hematopoietic stem cell transplantation (allo-HSCT), associated with poor outcomes. Previous studies have demonstrated the protective effect of CMV-R against relapse after allo-HSCT for acute myeloblastic leukemia (AML). However, this impact remains unclear in acute lymphoblastic leukemia (ALL). We conducted a retrospective study on 81 patients with ALL who received allo-HSCT after myeloablative conditioning regimen from matched sibling donors between 2016 and 2022. All patients underwent weekly monitoring for CMV-R by quantitative polymerase chain reaction assay from engraftment until day +100 post allo-HSCT, and received antiviral prophylaxis with acyclovir from day +1 to 6 months after allo-HSCT. Preemptive treatment was initiated when a viremia was higher than 150 copies/mL. The median age was 20 years (range, 5-50 years). After allo-HSCT, 35% of patients developed CMV-R after a median of 39 days (range, 19-100 days). After a median follow-up of 30 months (range, 1-93 months), CMV-R was an independent factor associated with lower cumulative incidence of relapse (CIR) (OR: 0.17; 95% CI [0.03 - 0.98], p = 0.04) without survival benefit. Further studies are needed to validate the protective effect of CMV-R on ALL relapse.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"125912"},"PeriodicalIF":0.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Social media in medicine: a personal perspective about opportunities, challenges, and best practice. 医学社交媒体：从个人角度看机遇、挑战和最佳实践。

Clinical hematology international Pub Date : 2024-11-23 eCollection Date: 2024-01-01 DOI: 10.46989/001c.125931

Mohamad Mohty, Bipin Savani

引用次数: 0

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT. 护士报告的高级细胞疗法培训需求：代表 EBMT 护士小组进行的调查。

Clinical hematology international Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124593

Michelle Kenyon, Sarah Jayne Liptrott, Annika Kisch, Jarl Mooyaart, Brian Piepenbroek, Daphna Hutt, Isabel Salcedo, Annalisa Ruggeri, Cristian Chabannon, Rose Ellard, John Murray

{"title":"Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.","authors":"Michelle Kenyon, Sarah Jayne Liptrott, Annika Kisch, Jarl Mooyaart, Brian Piepenbroek, Daphna Hutt, Isabel Salcedo, Annalisa Ruggeri, Cristian Chabannon, Rose Ellard, John Murray","doi":"10.46989/001c.124593","DOIUrl":"10.46989/001c.124593","url":null,"abstract":"Background: Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits.Objectives: This study aimed to describe nurses' training needs in relation to ATMP management and patient care.Methods: A cross-sectional online survey was performed by the European Society for Blood and Marrow Transplantation, based on a previously tested questionnaire developed in the UK.Findings: 109 complete responses from 86 different centers from 24 countries were returned (1207 distributed). Over 1/3 reported experience delivering licensed ATMPs (CAR-T). High-priority training areas included a general introduction to ATMPs, toxicity management, product-specific information, and regulatory frameworks for ATMPs. A clear need for ATMP-specific training exists and is regarded as important. Training prior to implementation is key and should be supported by ongoing competency maintenance. Counseling, patient support, and long-term follow-up are identified for future training and opportunities for nurse experience sharing in this rapidly evolving field.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"104-113"},"PeriodicalIF":0.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Untangling the clonal architecture in a case of acute myeloid leukaemia with multiple cytogenetically unrelated clones. 解开一例急性髓性白血病患者的细胞遗传无关克隆结构。

Clinical hematology international Pub Date : 2024-11-12 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124931

Helen Cashman, Andrew J Wilson, Ke Xu, Elisabeth Nacheva, Robert Baker, Rajeev Gupta

引用次数: 0

Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report. 妊娠期多发性骨髓瘤恶性脊髓压迫的处理：病例报告。

Clinical hematology international Pub Date : 2024-10-23 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124664

Khushnuma Mullanfiroze, Charlotte Jones, David Williams, Matias Vieira, Ashutosh Wechalekar, Xenofon Papanikolaou, Rakesh Popat, Charalampia Kyriakou, Ke Xu

引用次数: 0

Overview of approved CAR-T products and utility in clinical practice. 已获批准的 CAR-T 产品和临床实用性概述。

Clinical hematology international Pub Date : 2024-10-23 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124277

Shakthi T Bhaskar, Bhagirathbhai Dholaria, Bipin N Savani, Salyka Sengsayadeth, Olalekan Oluwole

引用次数: 0

Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. 慢性移植物抗宿主病相关病症的多学科管理。

Clinical hematology international Pub Date : 2024-10-21 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124926

Rahul Shah, Danielle Murphy, Melissa Logue, James Jerkins, Andrew Jallouk, Kassim Adetola, Olalekan Oluwole, Reena Jayani, Eden Biltibo, Tae K Kim, Salyka Sengsayadeth, Wichai Chinratanalab, Carrie Kitko, Bipin Savani, Bhagirathbhai Dholaria

{"title":"Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.","authors":"Rahul Shah, Danielle Murphy, Melissa Logue, James Jerkins, Andrew Jallouk, Kassim Adetola, Olalekan Oluwole, Reena Jayani, Eden Biltibo, Tae K Kim, Salyka Sengsayadeth, Wichai Chinratanalab, Carrie Kitko, Bipin Savani, Bhagirathbhai Dholaria","doi":"10.46989/001c.124926","DOIUrl":"10.46989/001c.124926","url":null,"abstract":"Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor. While the mainstay of treatment has remained systemic immunosuppression with glucocorticoids, progress has been made within the last few years with approvals of three oral agents to treat steroid-refractory cGVHD: ibrutinib, ruxolitinib, and belumosudil. Iatrogenesis contributes a significant portion of the morbidity experienced by patients with cGVHD, primarily from glucocorticoids. This review highlights the myriad impacts of cGVHD, including and beyond the traditional organ systems captured by the National Institutes of Health Consensus Criteria, including iatrogenic complications of long-term immunosuppression. It presents the implications of cGVHD and its treatment on cardiovascular and metabolic health, bone density, endocrine function, sexual health, and ocular and pulmonary disease and outlines a framework around the comprehensive multidisciplinary approach for its evaluation and management.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"74-88"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary GvHD: is it time to change the NIH diagnostic criteria? 肺缺血性坏死：现在是改变美国国立卫生研究院诊断标准的时候了吗？

Clinical hematology international Pub Date : 2024-10-19 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124551

Martina Canichella, Poalo de Fabritiis

引用次数: 0

Delivering an impactful presentation: a practical guide. 发表有影响力的演讲：实用指南。

Clinical hematology international Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI: 10.46989/001c.124436

Mohamad Mohty

引用次数: 0